TECH BUYER Jul 2020 - IDC Perspective - Doc # CA45672920

Better Data-Driven Healthcare: The State of Real-World Evidence in Canada, 2020

By: Mark SchruttStrategic Advisor, Public Sector & Innovation Research, Jason BremnerResearch Vice President, Industry and Business Solutions

Abstract

This IDC Perspective outlines the current status of Canada's national strategy to optimize the use of real-world evidence based on real-world data for drugs and medical devices and places it within the international context, focusing on parallel activities in the United States and the EU. Real-world evidence derived from RWD presents a significant opportunity to enhance the evidence generated from randomized controlled trials. However, RWE continues to be viewed by most stakeholders as lower quality and less reliable than randomized controlled trials, which continue to be viewed as generating superior evidence. As a result, there are higher comfort levels for using RWE in relation to economic decision making such as HTA recommendations and conditional outcomes-based contracting than for using RWE as evidence of post-market effectiveness.

Processes to create a national framework for use of RWE are still at an early stage. Although Canada has separate framework development processes for pharmaceutical drugs and medical devices, it appears to have similar goals and outlines, although slightly different participant structures.

"The market would welcome a national framework that provides clear guidance on consistent processes, timing, and methods for use of RWE in health sector regulatory decisions," says Mark Schrutt, IDC Canada's strategic advisor, Innovation and Public Sector Research.


Coverage

Content


Get More

When you purchase this document, the purchase price can be applied to the cost of an annual subscription, giving you access to more research for your investment.



Related Links

Do you have questions about this document
or available subscriptions?

Contact Us